Innate Pharma SA (FR:IPH) has released an update.
Innate Pharma SA has reported promising clinical trial results and a solid cash position in its first half of 2024 update. The company showcased positive Phase 2 outcomes for lacutamab in treating mycosis fungoides and is moving forward with other promising oncology treatments, including a proprietary anti-Nectin-4 ADC, IPH45. With a financial runway extending to the end of 2025, Innate Pharma remains on a strategic path towards growth and development in cancer therapy.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
